Cargando…

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020

BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Ranawaka APM, Mok, Chris KP, Tsang, Owen TY, Lv, Huibin, Ko, Ronald LW, Wu, Nicholas C, Yuan, Meng, Leung, Wai Shing, Chan, Jacky MC, Chik, Thomas SH, Choi, Chris YC, Leung, Kathy, Chan, Kin Ho, Chan, Karl CK, Li, Ka-Chi, Wu, Joseph T, Wilson, Ian A, Monto, Arnold S, Poon, Leo LM, Peiris, Malik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/
https://www.ncbi.nlm.nih.gov/pubmed/32347204
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421
_version_ 1783527541003255808
author Perera, Ranawaka APM
Mok, Chris KP
Tsang, Owen TY
Lv, Huibin
Ko, Ronald LW
Wu, Nicholas C
Yuan, Meng
Leung, Wai Shing
Chan, Jacky MC
Chik, Thomas SH
Choi, Chris YC
Leung, Kathy
Chan, Kin Ho
Chan, Karl CK
Li, Ka-Chi
Wu, Joseph T
Wilson, Ian A
Monto, Arnold S
Poon, Leo LM
Peiris, Malik
author_facet Perera, Ranawaka APM
Mok, Chris KP
Tsang, Owen TY
Lv, Huibin
Ko, Ronald LW
Wu, Nicholas C
Yuan, Meng
Leung, Wai Shing
Chan, Jacky MC
Chik, Thomas SH
Choi, Chris YC
Leung, Kathy
Chan, Kin Ho
Chan, Karl CK
Li, Ka-Chi
Wu, Joseph T
Wilson, Ian A
Monto, Arnold S
Poon, Leo LM
Peiris, Malik
author_sort Perera, Ranawaka APM
collection PubMed
description BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. AIM: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. METHODS: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT(90)) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. RESULTS: IgG and IgM RBD ELISA, MN and PRNT(90) were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT(90) tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. CONCLUSION: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT(90), is a valid approach for large-scale sero-epidemiology studies.
format Online
Article
Text
id pubmed-7189648
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-71896482020-04-30 Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 Perera, Ranawaka APM Mok, Chris KP Tsang, Owen TY Lv, Huibin Ko, Ronald LW Wu, Nicholas C Yuan, Meng Leung, Wai Shing Chan, Jacky MC Chik, Thomas SH Choi, Chris YC Leung, Kathy Chan, Kin Ho Chan, Karl CK Li, Ka-Chi Wu, Joseph T Wilson, Ian A Monto, Arnold S Poon, Leo LM Peiris, Malik Euro Surveill Research BACKGROUND: The ongoing coronavirus disease (COVID-19) pandemic has major impacts on health systems, the economy and society. Assessing infection attack rates in the population is critical for estimating disease severity and herd immunity which is needed to calibrate public health interventions. We have previously shown that it is possible to achieve this in real time to impact public health decision making. AIM: Our objective was to develop and evaluate serological assays applicable in large-scale sero-epidemiological studies. METHODS: We developed an ELISA to detect IgG and IgM antibodies to the receptor-binding domain (RBD) of the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated its sensitivity and specificity in combination with confirmatory microneutralisation (MN) and 90% plaque reduction neutralisation tests (PRNT(90)) in 51 sera from 24 patients with virologically confirmed COVID-19 and in age-stratified sera from 200 healthy controls. RESULTS: IgG and IgM RBD ELISA, MN and PRNT(90) were reliably positive after 29 days from illness onset with no detectable cross-reactivity in age-stratified controls. We found that PRNT(90) tests were more sensitive in detecting antibody than MN tests carried out with the conventional 100 tissue culture infectious dose challenge. Heparinised plasma appeared to reduce the infectivity of the virus challenge dose and may confound interpretation of neutralisation test. CONCLUSION: Using IgG ELISA based on the RBD of the spike protein to screen sera for SARS-CoV-2 antibody, followed by confirmation using PRNT(90), is a valid approach for large-scale sero-epidemiology studies. European Centre for Disease Prevention and Control (ECDC) 2020-04-23 /pmc/articles/PMC7189648/ /pubmed/32347204 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Perera, Ranawaka APM
Mok, Chris KP
Tsang, Owen TY
Lv, Huibin
Ko, Ronald LW
Wu, Nicholas C
Yuan, Meng
Leung, Wai Shing
Chan, Jacky MC
Chik, Thomas SH
Choi, Chris YC
Leung, Kathy
Chan, Kin Ho
Chan, Karl CK
Li, Ka-Chi
Wu, Joseph T
Wilson, Ian A
Monto, Arnold S
Poon, Leo LM
Peiris, Malik
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title_full Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title_fullStr Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title_full_unstemmed Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title_short Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
title_sort serological assays for severe acute respiratory syndrome coronavirus 2 (sars-cov-2), march 2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/
https://www.ncbi.nlm.nih.gov/pubmed/32347204
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421
work_keys_str_mv AT pereraranawakaapm serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT mokchriskp serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT tsangowenty serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT lvhuibin serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT koronaldlw serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT wunicholasc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT yuanmeng serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT leungwaishing serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT chanjackymc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT chikthomassh serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT choichrisyc serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT leungkathy serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT chankinho serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT chankarlck serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT likachi serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT wujosepht serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT wilsoniana serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT montoarnolds serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT poonleolm serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020
AT peirismalik serologicalassaysforsevereacuterespiratorysyndromecoronavirus2sarscov2march2020